Study identifier:D1531C00018
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, open-label, multi-centre, multiple ascending dose study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML)
Acute Myeloid Leukemia
Phase 1
No
AZD1152, LDAC (low dose cytosine arabinoside)
All
4
Interventional
60 Years +
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.
Location
Location
LE CHESNAY CEDEX, France
Location
VILLEJUIF CEDEX, France
Location
CLEVELAND, OH, United States
Location
HOUSTON, TX, United States
Arms | Assigned Interventions |
---|---|
Experimental: 1 AZD1152 variable dose in combination with 20 mg of LDAC. (The LDAC is given twice daily.) | Drug: AZD1152 Variable dose via a 7-day continuous infusion Drug: LDAC (low dose cytosine arabinoside) 20 mg subcutaneous injection given twice daily |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.